Influence of XXXX genotype 1 subtypes on the virus response to PEG interferon alpha-2a plus @entity5371 therapy.

@entity1 @entity3531 @entity645 @entity5371 @entity3027 @entity17734
New factors that influence the viral response in @entity3531 non-genotype 2/3 @entity1 must be identified in order to optimize anti-HCV treatment. This multicenter prospective study evaluates the influence of @entity3531 variability and pharmacological parameters on the virological response of these @entity1 to pegylated interferon a2a (peg-IFN-a2a: 180   g/week) and @entity5371 ( @entity17734 ; 800-1,200 mg/day) for 48 weeks. @entity3531 subtypes were identified by sequencing the NS5B region. Serum RBV and peg- @entity3027 2a concentrations were measured at weeks 4 and 12. The 115 @entity1 (67 @entity1 ; median age = 49, range 31-76) included 64 who had never been treated and 27 co-infected with @entity645 . The mean baseline @entity3531 RNA was 6.30    0.06 log IU/ml and the @entity3531 genotypes were: G1 (n = 93) with 1a (n = 37) and 1b (n = 50), G4 (n = 20) and G5 (n = 2). Most @entity1 (79/108; 73%) had an early virological response. Independent predictors of an early virological response were interferon naive @entity1 (OR=    2.98, 95% CI: 1.15-7.72) and RBV of >2,200 ng/ml at week 12 (OR = 3.41, 95% CI: 1.31-8.90). Forty of 104 @entity1 (38%) had a sustained virological response. The only independent predictors of a sustained virological response were subtype 1b (OR = 6.82, 95% CI: 1.7-26.8), and @entity3531 RNA <15 IU/ml at week 12 (OR = 25, 95% CI: 6.4-97.6). Thus a serum RBV concentration of >2,200 ng/ml was associated with an early virological response and @entity1 infected with @entity3531 subtype 1b had a better chance of a sustained virological response than did those infected with subtype 1a.
